# Use of Immune Globulin Plus Rituximab for Desensitization in Highly HLA Sensitized Patients Awaiting Deceased Donor Kidney Transplantation

> **NCT01178216** · PHASE1,PHASE2 · COMPLETED · sponsor: **Stanley Jordan, MD** · enrollment: 41 (actual)

## Conditions studied

- End Stage Renal Disease

## Interventions

- **BIOLOGICAL:** Rituxan

## Key facts

- **NCT ID:** NCT01178216
- **Lead sponsor:** Stanley Jordan, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-09
- **Primary completion:** 2017-07-28
- **Final completion:** 2017-07-28
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2018-10-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01178216

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01178216, "Use of Immune Globulin Plus Rituximab for Desensitization in Highly HLA Sensitized Patients Awaiting Deceased Donor Kidney Transplantation". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT01178216. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*